Streptozosin

Streptozosin

SCHEMBL10201155

CN(N=O)C(=O)NC1[C@@H](O)OC(CO)[C@@H](O)[C@H]1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 1.00
KDM4E B2RXH2 1/20 1.00
CYP2D6 P10635 1/20 1.00
CYP2C19 P33261 1/20 1.00
HK2 P52789 5/20 0.45
HK1 P19367 4/20 0.45
MAPK1 P28482 2/20 0.42
PYGB P11216 6/20 0.39
GAA P10253 1/20 0.39
ALDH1A1 P00352 1/20 0.38
THRB P10828 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Streptozosin SCHEMBL444089 1.00 LMNA (1.00) LMNAKDM4ECYP2D6CYP2C19HK2
Streptozosin SCHEMBL18402590 1.00 LMNA (1.00) LMNAKDM4ECYP2D6CYP2C19HK2
Streptozosin SCHEMBL4748 1.00 LMNA (1.00) LMNAKDM4ECYP2D6CYP2C19HK2
Streptozosin SCHEMBL13840968 1.00 LMNA (1.00) LMNAKDM4ECYP2D6CYP2C19HK2
Streptozosin SCHEMBL17327962 1.00 LMNA (1.00) LMNAKDM4ECYP2D6CYP2C19HK2
Streptozosin SCHEMBL15012795 1.00 LMNA (1.00) LMNAKDM4ECYP2D6CYP2C19HK2
Streptozosin SCHEMBL17328035 1.00 LMNA (1.00) LMNAKDM4ECYP2D6CYP2C19HK2
Streptozosin SCHEMBL10262780 1.00 LMNA (1.00) LMNAKDM4ECYP2D6CYP2C19HK2
Streptozosin SCHEMBL18402588 1.00 LMNA (1.00) LMNAKDM4ECYP2D6CYP2C19HK2
Streptozosin SCHEMBL444088 1.00 LMNA (1.00) LMNAKDM4ECYP2D6CYP2C19HK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9353218-B2 Kit for multifunctional compounds forming crosslinked biomaterials ANGIOTECH PHARMACEUTICALS, INC. 2016-05-31 US disclosed
US-9326934-B2 Drug delivery from rapid gelling polymer composition ANGIOTECH INTERNATIONAL AG 2016-05-03 US disclosed
US-20130289235-A1 MULTIFUNCTIONAL COMPOUNDS FOR FORMING CROSSLINKED BIOMATERIALS AND METHODS OF PREPARATION AND USE ANGIOTECH PHARMACEUTICALS, INC. (CA) 2013-10-31 US disclosed
US-8486437-B2 Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use ANGIOTECH PHARMACEUTICALS (US), INC. (US) 2013-07-16 US disclosed
US-8481073-B2 Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use ANGIODEVICE INTERNATIONAL GMBH (CH) 2013-07-09 US disclosed
US-8460708-B2 Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use ANGIODEVICE INTERNATIONAL GMBH (CH) 2013-06-11 US disclosed
US-20130012683-A1 MULTIFUNCTIONAL COMPOUNDS FOR FORMING CROSSLINKED BIOMATERIALS AND METHODS OF PREPARATION AND USE ANGIOTECH PHARMACEUTICALS (US), INC. (US) 2013-01-10 US disclosed
US-20130012683-A1 MULTIFUNCTIONAL COMPOUNDS FOR FORMING CROSSLINKED BIOMATERIALS AND METHODS OF PREPARATION AND USE ANGIOTECH PHARMACEUTICALS (US), INC. (US) 2013-01-10 US disclosed
US-20120252905-A1 DRUG DELIVERY FROM RAPID GELLING POLYMER COMPOSITION ANGIOTECH INTERNATIONAL AG 2012-10-04 US disclosed
US-20120052040-A1 POLYMER COMPOSITIONS AND METHODS FOR THEIR USE ANGIOTECH INTERNATIONAL AG (CH) 2012-03-01 US disclosed
US-20120039980-A1 COMPOSITIONS AND SYSTEMS FOR FORMING CROSSLINKED BIOMATERIALS AND ASSOCIATED METHODS OF PREPARATION AND USE ANGIODEVICE INTERNATIONAL GMBH (CH) 2012-02-16 US disclosed
US-20120041481-A1 COMPOSITIONS AND SYSTEMS FOR FORMING CROSSLINKED BIOMATERIALS AND ASSOCIATED METHODS OF PREPARATION AND USE ANGIODEVICE INTERNATIONAL GMBH (CH) 2012-02-16 US disclosed
US-8067031-B2 Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use ANGIODEVICE INTERNATIONAL GMBH (CH) 2011-11-29 US disclosed
US-20100268288-A1 ELECTRICAL DEVICES AND ANTI-SCARRING AGENTS ANGIOTECH INTERNATIONAL AG (CH) 2010-10-21 US disclosed
US-20100092536-A1 IMPLANTABLE SENSORS AND IMPLANTABLE PUMPS AND ANTI-SCARRING AGENTS ANGIOTECH INTERNATIONAL AG (CH) 2010-04-15 US disclosed
US-20090226500-A1 SUTURES AND ANTI-SCARRING AGENTS ANGIOTECH PHARMACEUTICALS, INC (CA) 2009-09-10 US disclosed
US-20090214652-A1 SOFT TISSUE IMPLANTS AND ANTI-SCARRING AGENTS ANGIOTECH INTERNATIONAL AG (CH) 2009-08-27 US disclosed
US-20090203632-A1 COMPOSITIONS AND METHODS FOR TREATING CONTRACTURE ANGIOTECH INTERNATIONAL AG (CH) 2009-08-13 US disclosed
US-20080312315-A1 Multifunctional Compounds for Forming Crosslinked Biomaterials and Methods of Preparation and Use ANGIOTECH PHARMACEUTICALS(US),INC. (US) 2008-12-18 US disclosed
US-20080058579-A1 Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors ANGIOTECH INTERNATIONAL AG (CH) 2008-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120039980-A1 COMPOSITIONS AND SYSTEMS FOR FORMING CROSSLINKED BIOMATERIALS AND ASSOCIATED METHODS OF PREPARATION AND USE ILK, FN1, COL1A1 LMNA 865/4885KDM4E 4239/4885CYP2D6 2963/4885
US-20090203632-A1 COMPOSITIONS AND METHODS FOR TREATING CONTRACTURE COL2A1, FN1, TNNC1 LMNA 1072/4885KDM4E 3469/4885CYP2D6 4350/4885
US-20120252905-A1 DRUG DELIVERY FROM RAPID GELLING POLYMER COMPOSITION PGF, VCAM1, COL14A1 LMNA 1945/4885KDM4E 3013/4885CYP2D6 1593/4885
US-20090214652-A1 SOFT TISSUE IMPLANTS AND ANTI-SCARRING AGENTS MMP1, COL2A1, FN1 LMNA 1905/4885KDM4E 2785/4885CYP2D6 4288/4885
US-20090226500-A1 SUTURES AND ANTI-SCARRING AGENTS COL1A1, COL2A1, COL14A1 LMNA 844/4885KDM4E 2701/4885CYP2D6 4881/4885
US-20100092536-A1 IMPLANTABLE SENSORS AND IMPLANTABLE PUMPS AND ANTI-SCARRING AGENTS MMP1, CDKN1A, MKI67 LMNA 3440/4885KDM4E 1403/4885CYP2D6 4729/4885
US-20120052040-A1 POLYMER COMPOSITIONS AND METHODS FOR THEIR USE COL2A1, COL14A1, COL1A1 LMNA 821/4885KDM4E 3267/4885CYP2D6 4883/4885
US-20080312315-A1 Multifunctional Compounds for Forming Crosslinked Biomaterials and Methods of Preparation and Use ILK, PLOD3, MMP1 LMNA 1008/4885KDM4E 3108/4885CYP2D6 2237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.